ORCHIDCHEM 
Orchid Chemicals & Pharmaceuticals Ltd
How do you think orchidchem will perform against the NIFTY? Pick this stock
CAPITAL4 COMMUNITY
All: Members who that have picked this stock: 60
58 outperforms
2 underperforms
Stars: Top Investors who have picked this stock: 9
9 outperforms
0 underperforms
CLASSIFICATION | SECTOR | INDUSTRY |
|---|---|---|
| Primary | Pharma & Healthcare | Pharmaceuticals |
SNAPSHOT
- BSE Code / NSE Ticker
- 524372 / ORCHIDCHEM
- Last traded time
- 2012-05-23 15:59:09
- Last traded on
- BSE
- Intra-day Low / High
- 117.4 / 124.1
- 52w closing Low / High
- 119.3 / 292.0
- Today Volume
- 2,898,530
- 30d avg Daily Volume
- 2,391,259
- Market Cap
- INR 840.5 cr
- P/E Ratio TTM
- 7.85
- Historical Performance
- Today
- Weekly
- Monthly
- 3 Months
- 1 Year
- -3.6%
- -6.2%
- -33.8%
- -33.6%
- -54.4%
valuation snapshotpeer comparisonfinancialsshare holdingmf holdingcommunity picksbrokerage picks futures & options
Industry: Pharmaceuticals
| Parameter++ Click on Parameter for definition | Value | Industry Median | Industry Weighted Avg | Parameter ++ | Per Share Value | |
|---|---|---|---|---|---|---|
| Gross Margin | 27.6% | 20.2% | 30.9% | Last Closing Price | 119.30 | |
| Core Operating Margin | 9.8% | 6.1% | 12.2% | Book Value per share | 50.24 | |
| EBIT Margin | 17.4% | 10.8% | 41.2% | Long-term Debt per share | 81.75 | |
| Net Profit Margin | 9.6% | 5.1% | 30.3% | Enterprise Value per share | 118.98 | |
| Adj Net Profit Margin | 9.6% | 5.0% | 14.4% | Net Cash per share | -5.44 | |
| Return on Assets | 5.4% | 5.5% | 21.2% | Cash from Operations per share | 13.83 | |
| Return on Capital Employed | 12.2% | 12.2% | 30.9% | Free Cashflow per share | -3.88 | |
| Return on Equity | 14.1% | 9.2% | 30.7% | Sales per share | 73.69 | |
| Asset Turnover | 0.56 | 0.97 | 0.70 | Total income per share | 79.33 | |
| Cash Return (FCFF/EV) | 0.7% | -40.8% | 0.3% | PAT per share | 7.07 | |
| Adj Price-to-Earnings TTM ** | 7.85 | 26.00 | -- | Adj PAT per share | 7.04 | |
| Adj Price-to-Earnings | 5.29 | 17.07 | 25.53 | |||
| Price-to-Book | 0.74 | 1.22 | 3.73 | |||
| Price-to-FCF | -- | -- | -849.98 | |||
| EV / EBITDA | 6.42 | 9.34 | 9.26 | |||
| Price-to-Sales | 0.51 | 0.74 | 3.69 | |||
| Financial Leverage | 2.63 | 1.46 | 1.45 | |||
| Interest Coverage | 2.50 | 4.51 | 14.57 | |||
| Debt to MarketCap | 2.20 | 0.33 | 0.12 | |||
| 1y Dividend Yield | 3.0% | 0.2% | 1.0% | |||
| 1y Dividend Payout | 16.1% | 3.4% | 24.3% | |||
| 3y Dividend Yield | 4.9% | 0.6% | 0.8% | |||
| 3y Dividend Payout | -- | 9.4% | 25.0% | |||
| 3y Sales Growth CAGR | 10.3% | 13.7% | 12.9% | |||
| 3y Earnings Growth CAGR | -4.7% | 0.6% | 39.7% |
++ All values calculated using standalone 2011 Financial Results (unless otherwise mentioned)
** From last 4 quarterly results
CAPITAL4 COMMUNITY
STOCK SCREENERS
INDIA CAPITAL MARKETS
ORCHIDCHEM IN THE NEWS
- May-16 8:07 Orchid Chemicals & Pharmaceuticals net profit declines 66.47% in the March 2012 quarter
- May-08 12:39 Orchid Pharma receives USFDA approval for Naratriptan Tabs ANDA
- May-08 11:09 Orchid Chemicals & Pharmaceuticals to consider dividend
- Apr-05 9:25 Hon'ble High Court approves scheme of amalgamation of Orchid Chemicals & Pharmaceuticals
- Feb-08 15:00 Orchid Chemicals & Pharmaceuticals reports net loss of Rs 10.12 crore in the December 2011 quarter
- Feb-07 11:07 Orchid Chemicals & Pharmaceuticals receives USFDA approval
- Jan-11 9:56 Orchid Chemicals & Pharmaceuticals' board approves scheme of amalgamation
- Dec-30 16:28 Orchid Chemicals & Pharmaceuticals to hold board meeting
- Dec-23 11:28 Orchid's drug discovery research initiative with Merck advances anti-infective program meets preclinical milestone
TOP BLOGS
- Advice for – Tuesday, May 22, 2012
by ABHISHEK-PARAKH
(Recommendations: 6) - Money can be made in all market conditions
by ASHOKSHARMA
(Recommendations: 7) - The problem with historical returns
by ROHIT CHAUHAN
(Recommendations: 9) - Markets: What next?
by Nishit_Vadhavkar
(Recommendations: 8) - Nifty – RSI at sub 30. Highly Oversold – Bottoming out in next few sessions
by NOORESH MERANI
(Recommendations: 9) - Follow up: Gujarat reclaim & rubber products ltd
by ROHIT CHAUHAN
(Recommendations: 9) - Negative news drags the markets down
by Nishit_Vadhavkar
(Recommendations: 7) - Option strategy worked will in such unpredictable market
by ASHOKSHARMA
(Recommendations: 8) - Sensex- Technical Outlook and Trading Levels, 8 April 2012
by D_Sathiamoorthy
(Recommendations: 5) - Insourcing vs. outsourcing government functions: A setback for public sector production of elementary education
by AJAY SHAH
(Recommendations: 7) - Crucial Week Ahead
by Nishit_Vadhavkar
(Recommendations: 8) - A few contrarian thoughts
by ROHIT CHAUHAN
(Recommendations: 8)
Company and Mutual Fund Finder
| Company: | 3ABCDEFGHIJKLMNOPQRSTUVWXYZ |
| Indices: | NIFTY | SENSEX | BSE 100 | BSE 200 | BSE 500 | BSE MIDCAP | BSE SMALLCAP | BSE AUTO | BSE BANKEX | BSE CD | BSE CG | BSE FMCG | BSE HC | BSE IT | BSE METAL | BSE OIL | BSE POWER | BSE PSU | BSE REALTY | BSE TECK | BSE DOLLEX | DOLLEX 100 | DOLLEX 200 | NIFTY JUNIOR | CNX MIDCAP | NIFTY MID50 | BANK NIFTY | CNX IT | CNX100 | CNX 500 | CNX DEFTY |
| Mutual Funds: | AIG Global Investment | AXIS | Baroda Pioneer | Benchmark | Bharti AXA | Birla Sun Life | Canara Robeco | Deutsche | DSP BlackRock | Edelweiss | Escorts | Fidelity | Fortis | Franklin Templeton | HDFC | HSBC | ICICI Prudential | IDBI | IDFC | ING | JM Financial | JP Morgan | Kotak Mahindra | L&T | LIC | Mirae Asset | Morgan Stanley | Motilal Oswal | Peerless | Pramerica | PRINCIPAL | Quantum | Reliance | Religare | Sahara | SBI | Shinsei | Sundaram BNP Paribas | Tata | Taurus | UTI |